Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment of autoimmune diseases, today announced the ...

GSK (GSK) came out with quarterly earnings of $0.59 per share, beating the Zacks Consensus Estimate of $0.53 per share. This compares to earnings of $0.72 per share a year ago. These figures are ...

Stay updated on the latest financial news and upcoming IPOs/SPACs with this article covering Titan America, Smithfield Foods, ...

Cartesian Therapeutics (NASDAQ:RNAC – Get Free Report)‘s stock had its “buy” rating reaffirmed by research analysts at ...

H.C. Wainwright reaffirmed a Buy rating on Cartesian Therapeutics shares, maintaining the $45.00 price target, representing a ...

Cartesian Therapeutics has secured an agreement from the US Food and Drug Administration (FDA) under the Special Protocol ...

Julian Harrison, an analyst from BTIG, reiterated the Buy rating on Cartesian Therapeutics (RNAC – Research Report). The associated price ...

The CAR T-cell therapy market size was valued at $2.6 billion in 2022 and is estimated to reach $35.9 billion by 2032, exhibiting a CAGR of 28.5% by 2032.

In a report released today, Gil Blum from Needham maintained a Buy rating on Cartesian Therapeutics (RNAC – Research Report), with a price ...

Trial on track to commence in 1H25FREDERICK, Md., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA ...

The company also continues to study Descartes-08 in other autoimmune diseases and has plans for a basket trial in pediatric patients.

Find the latest Cartesian Therapeutics, Inc. RNAC analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports.